Capitalist Insider: Analysts just piled into Scribe with up to 183% upside targets
Historic low Bitcoin volatility signals a 30% move within 60 days
Hello Capitalist Insiders!
Get the inside edge on what you need to know today:
Analysts just piled into Scribe with up to 183% upside targets
Historic low Bitcoin volatility signals a 30% move within 60 days
Analysts bet big on Freenome’s blood-based cancer screening platform
Cursor is now SpaceX property after $60 billion acquisition closes
The Capitalist Insider is not financial advice.
We simply wish to provide you, our most dedicated supporters, with the best available insights available. We appreciate your support, if it wasn’t for you, we would not be able to do what we do.
Scribe Therapeutics draws bullish ratings with 183% upside
Three Wall Street firms initiated coverage of Scribe Therapeutics less than a month after its IPO, with price targets of $37 to $60 implying 75% to 183% upside.
